tldrdailynews.com logo

Novartis Approaches $12 Billion Acquisition of Avidity Biosciences

1 min read
Source: Financial Times
Novartis Approaches $12 Billion Acquisition of Avidity Biosciences
Photo: Financial Times
TL;DR

Novartis is set to acquire Avidity Biosciences for $12 billion, marking a significant move in the pharmaceutical industry.

Topics:top-newsbusiness#acquisition#avidity-biosciences#business#mergers-and-acquisitions#novartis#pharmaceuticals
Share this article
  1. Novartis to buy Avidity Biosciences for $12bn  Financial Times
  2. Novartis to buy U.S. biotech firm Avidity Biosciences for about $12 billion in cash  CNBC
  3. Novartis Said to Near at Least $70-Per-Share Deal for Avidity  Bloomberg.com
  4. Novartis to buy RNA-focused Avidity in $12B deal  statnews.com
  5. Novartis is said to near acquisition of Avidity Biosciences for more than $70 a share (NVS:NYSE)  Seeking Alpha

Want the full story? Read the original reporting

Read on Financial Times